Recent litigation, changes in drug manufacturer policies and reimbursement trends have raised questions about the future and direction of the 340B program and the contract pharmacy model. While the 340B program has long brought to the surface conflicting business objectives of 340B covered entities and drug manufacturers, the current environment is unprecedented. More than 20 drug manufacturers have implemented restrictions on access to 340B pricing for drugs dispensed through contract pharmacies, and the Third Circuit Court of Appeals has ruled that manufacturers are not required to provide 340B pricing to an unlimited number of contract pharmacies and are authorized to impose 340B pricing restrictions.
At the same time, state Medicaid agencies, Medicaid managed care plans, and other payers continue to implement 340B-specific billing and reimbursement policies. 340B covered entities are also considering lines of business beyond community retail, such as specialty, home infusion, and ambulatory infusion center utilization. These developments can impact 340B pharmacy operations and finances differently depending on how a pharmacy is structured and operated and have led to dispensing models beyond contract pharmacy. Join our panelists in an educational conversation about the current state of the 340B program and an innovative dialog about what may be to come.
Bass, Berry & Sims healthcare attorneys Jeff Davis, Michael Hess, and Shannon Wiley will provide an overview of the recent 340B pharmacy developments and highlight the latest trends in pharmacy structuring and operations, including considerations related to ownership, management, licensing, and the possibility of alternative arrangements. The panel will also share their predictions for the future of 340B pharmacy arrangements
Join us on April 25, 2023, at 12:00 p.m. CST to learn more about the future of pharmacy arrangements.
Who Should Attend?
- In-house legal counsel of pharmacies, 340B covered entities, and pharmacy management companies.
- Private equity and other investors.
- Pharmacy leaders and managers.
- Pharmacy management company managers and leaders.
- 340B program stakeholders.
- Finance department leaders.
The webinar is pending approval for 1.5 hours of General Tennessee CLE credit. Certificate of completion and other necessary application forms will be provided for use in other jurisdictions.